OMEROS CORP Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
OMEROS CORP (OMER) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $11.63 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-12
- OMEROS CORP share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $13.21, a 52.89% increase year-over-year.
- OMEROS CORP share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $8.64, a 146.86% increase year-over-year.
- OMEROS CORP share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $3.50, a 16.67% increase year-over-year.
- OMEROS CORP share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $3.00, a 69.20% decline year-over-year.
- OMEROS CORP share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $3.30, a 1.85% increase from fiscal 2024.
- OMEROS CORP share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $3.24, a 7.64% increase from fiscal 2023.
- OMEROS CORP share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $3.01, a 21.00% decline from fiscal 2022.
- OMEROS CORP share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $3.81, a 75.16% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 1 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $11.63 10-Q · filed 2026-08-12 | ||||
| 2026-03-31 | $13.21 10-Q · filed 2026-05-13 | ||||
| 2025-12-31 | $3.30 10-K · filed 2026-03-31 | ||||
| 2025-09-30 | $3.29 10-Q · filed 2025-11-13 | ||||
| 2025-06-30 | $3.29 10-Q · filed 2025-08-14 | ||||
| 2025-03-31 | $8.64 10-Q · filed 2025-05-15 | ||||
| 2024-12-31 | $3.24 10-K · filed 2025-03-31 | ||||
| 2024-09-30 | $3.13 10-Q · filed 2024-11-13 | ||||
| 2024-06-30 | $3.10 10-Q · filed 2024-08-07 | ||||
| 2024-03-31 | $3.50 10-Q · filed 2024-05-15 | ||||
| 2023-12-31 | $3.01 10-K · filed 2024-04-01 | ||||
| 2023-09-30 | $3.13 10-Q · filed 2023-11-09 | ||||
| 2023-06-30 | $5.20 10-Q · filed 2023-08-09 | ||||
| 2023-03-31 | $3.00 10-Q · filed 2023-05-09 | ||||
| 2022-12-31 | $3.81 10-K · filed 2023-03-13 | ||||
| 2022-09-30 | $3.96 10-Q · filed 2022-11-09 | ||||
| 2022-06-30 | $7.29 10-Q · filed 2022-08-09 | ||||
| 2022-03-31 | $9.74 10-Q · filed 2022-05-10 | ||||
| 2021-12-31 | $15.34 10-K · filed 2022-03-01 | ||||
| 2021-09-30 | $15.44 10-Q · filed 2021-11-09 | ||||
| 2021-07-31 | $14.99 10-Q · filed 2021-08-09 | ||||
| 2021-06-30 | $18.53 10-Q · filed 2021-08-09 | ||||
| 2021-03-31 | $19.09 10-Q · filed 2021-05-10 | ||||
| 2020-12-31 | $12.29 10-K · filed 2021-03-01 | ||||
| 2020-09-30 | $12.36 10-Q · filed 2020-11-09 | ||||
| 2020-06-30 | $12.37 10-Q · filed 2020-08-10 | ||||
| 2020-03-31 | $11.95 10-Q · filed 2020-05-11 | ||||
| 2019-12-31 | $14.23 10-K · filed 2020-03-02 | ||||
| 2019-09-30 | $14.17 10-Q · filed 2019-11-12 | ||||
| 2019-06-30 | $13.93 10-Q · filed 2019-08-08 | ||||
| 2019-03-31 | $13.49 10-Q · filed 2019-05-09 | ||||
| 2018-12-31 | $15.01 10-K · filed 2019-03-01 | ||||
| 2018-09-30 | $14.91 10-Q · filed 2018-11-08 | ||||
| 2018-06-30 | $14.28 10-Q · filed 2018-08-09 | ||||
| 2018-03-31 | $14.49 10-Q · filed 2018-05-10 | ||||
| 2017-12-31 | $13.14 10-K · filed 2018-03-01 | ||||
| 2017-09-30 | $12.70 10-Q · filed 2017-11-09 | ||||
| 2017-06-30 | $12.37 10-Q · filed 2017-08-08 | ||||
| 2017-03-31 | $11.55 10-Q · filed 2017-05-10 | ||||
| 2016-12-31 | $10.72 10-K · filed 2017-03-16 | ||||
| 2016-09-30 | $10.85 10-Q · filed 2016-11-09 | ||||
| 2016-06-30 | $10.84 10-Q · filed 2016-08-09 | ||||
| 2016-03-31 | $10.31 10-Q · filed 2016-05-10 | ||||
| 2015-12-31 | $17.90 10-K · filed 2016-03-15 | ||||
| 2015-09-30 | $19.26 10-Q · filed 2015-11-09 | ||||
| 2015-06-30 | $20.74 10-Q · filed 2015-08-10 | ||||
| 2015-03-31 | $21.46 10-Q · filed 2015-05-11 | ||||
| 2014-12-31 | $11.72 10-K · filed 2015-03-16 | ||||
| 2014-09-30 | $12.00 10-Q · filed 2014-11-10 | ||||
| 2014-06-30 | $11.73 10-Q · filed 2014-08-11 | ||||
| 2014-03-31 | $0.00 10-Q · filed 2014-05-12 | ||||
| 2013-12-31 | $9.52 10-K · filed 2014-03-13 | ||||
| 2013-09-30 | $9.31 10-Q · filed 2013-11-07 | ||||
| 2013-06-30 | $5.30 10-Q · filed 2013-08-09 | ||||
| 2012-12-31 | $7.36 10-K · filed 2013-03-18 | ||||
| 2012-09-30 | $4.60 10-Q · filed 2012-11-09 | ||||
| 2012-06-30 | $4.54 10-Q · filed 2012-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |